Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$0.88
EPS est.
$1.15
EPS surprise
-23.48%
1-day move
-0.09%
Penumbra, Inc. reported earnings that fell short of expectations, particularly in EPS, which may raise concerns among investors. The stock reaction was minimal, declining only 0.09%. The lack of revenue data and management commentary leaves uncertainty about the company's performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.88 | $1.29 | -23.48% |
| Revenue | N/A | $403M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Penumbra, Inc. is a healthcare company that develops innovative medical devices for neuro and peripheral vascular conditions. With a market cap of $13 billion, it operates in the growing health care equipment sector, focusing on improving patient outcomes through advanced technology.
Last quarter
In Q1-2026, Penumbra reported an EPS of $0.82, falling short of the expected $1.11, leading to a 0.10% increase in stock the next day. The company did not provide specific revenue figures for that quarter.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
+3.00%
Avg 1-day reaction
-0.42%
Analysts are cautiously optimistic about Penumbra's upcoming earnings, with expectations for improved EPS and revenue compared to the previous quarter. However, the recent earnings miss has led to some skepticism.
Bull case
If Penumbra delivers better-than-expected earnings and demonstrates strong revenue growth, it could regain investor confidence and drive the stock higher.
Bear case
A continuation of earnings misses or weak guidance could lead to further declines in stock price, reflecting ongoing concerns about the company's growth trajectory.
Key metrics to watch
EPS
$1.29Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$403MTotal revenue reflects the company's sales performance and is crucial for assessing growth potential.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $1.29?
A beat on EPS would signal improved profitability and could boost investor confidence after the last quarter's miss.
Q2
What guidance will management provide for future revenue growth?
Clear guidance on revenue growth will be critical for assessing the company's ability to meet market expectations moving forward.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±14.1%
Why consensus could be wrong
The consensus may underestimate Penumbra's ability to recover from its recent earnings miss, as the company has historically shown resilience in bouncing back.
Supporting evidence
Penumbra has an 88% EPS beat rate historically, suggesting potential for positive surprises.
Options pricing indicates a significant expected move, which may reflect investor uncertainty rather than a lack of confidence in the company's fundamentals.
Key risk
If the company provides strong guidance for revenue growth, it could challenge the current cautious outlook.
Pre-commit to what would confirm each case.
The debate centers around whether Penumbra can rebound from its recent earnings miss and deliver strong growth in a competitive healthcare market.
Bull confirmed if
Earnings of $1.35 or higher with revenue exceeding $410M would confirm a strong recovery.
Bear confirmed if
Earnings below $1.14 or revenue under $393M would indicate ongoing challenges.
What the market is pricing for the move.
Implied Move
±19.6%
Historical Avg
±1.0%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±19.6% while PEN has averaged ±1.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
11.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
88.31%
of float
Insider
2.90%
of float
Holders
589
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
4,297,555 sh · $1.4B
10.91%
-0.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Penumbra beats expectations, history suggests a potential stock increase of around 0.10% the next day, confirming a positive turnaround.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data indicating an average drop of around 0.10% following earnings misses.
The lines on the call that would change the story.
HBK Investments L P
1,838,508 sh · $581.6M
4.67%
12.5%
Vanguard Capital Management LLC
1,709,877 sh · $540.9M
4.34%
0.9%
Vanguard Portfolio Management LLC
1,667,276 sh · $527.4M
4.23%
0.8%
State Street Corporation
1,243,258 sh · $393.3M
3.16%
4.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.